Malcolm Weir

Biography

Dr. Malcolm Weir, Ph.D. has been Chief Research & Development Officer and Executive Vice President at Sosei Group Corporation since June 23, 2015. Dr. Weir founded Heptares Therapeutics Ltd. July 2007 and has been its Chairman of the Board and Chief Executive Officer since July 2007. Dr. Weir joined Inpharmatica in June 2000 and serves as its Chief Scientific Officer. He served as Chief Executive Officer of Inpharmatica Ltd. since June 5, 2000. Previously, he was employed at Glaxo. He joined Glaxo in 1983. He served as Head of the Biomolecular Structure Unit in the Discovery Technology Division of GlaxoWellcome. He served as Divisional Director of the Molecular Sciences Division at Glaxo Wellcome Inc. since January 1999 and played a leading role in developing its Global scientific computing and proteomics strategies. He was responsible for project management of UK Research's entire target identification portfolio. Dr. weir was employed as an expert advisor by the Biotechnology and Biological Sciences Research Council (BBSRC) and several universities on structural biology. He was elected as Visiting Professor of Biochemistry at Imperial College, London in 1997. He served as a Director of Inpharmatica Ltd. Dr. Weir holds BSc and PhD in biochemistry and biophysics at Imperial College.

Research Interest

 Application of structural biology and modelling to Drug Discovery , Resulting  in the advancement of Clinical candidates  to a wide rangr of diseases.